anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), \[400 mg orally, twice daily\] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml\*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
BACKGROUND: The prevalence of obesity and its associated comorbidities continue to rise in the United States. Populations who are uninsured and from racial and ethnic minority groups continue to be disproportionately affected. These populations also experience fewer clinically meaningful outcomes in most weight loss trials. Weight gain prevention presents a useful strategy for individuals who experience barriers to weight loss. Given the often-limited weight management resources available to patients in primary care settings serving vulnerable patients, evaluating interventions with pragmatic designs may help inform the design of comprehensive obesity care delivered in primary care.
OBJECTIVE: This study aims to evaluate the effectiveness of Balance, a 2-arm, 12-month pragmatic randomized controlled trial of a digital weight gain prevention intervention, delivered to patients receiving primary care within federally qualified community health centers.
METHODS: Balance was a 2-arm, 12-month pragmatic randomized controlled trial of a digital weight gain prevention intervention delivered to individuals who had a BMI of 25-40 kg/m2, spoke English or Spanish, and were receiving primary care within a network of federally qualified community health centers in North Carolina. The Balance intervention was designed to encourage behavioral changes that result in a slight energy deficit. Intervention participants received tailored goal setting and tracking, skills training, self-monitoring, and responsive health coaching from registered dietitians. Weight was measured at regular primary care visits and documented in the electronic health record. We compared the percentage of ≤3% weight gain in each arm at 24 months after randomization-our primary outcome-using individual empirical best linear unbiased predictors from the linear mixed-effects model. We used individual empirical best linear unbiased predictors from participants with at least 1 electronic health record weight documented within a 6-month window centered on the 24-month time point.
RESULTS: We randomized 443 participants, of which 223 (50.3%) participants were allocated to the intervention arm. At baseline, participants had a mean BMI of 32.6 kg/m2. Most participants were Latino or Hispanic (n=200, 45.1%) or non-Latino or Hispanic White (n=115, 26%). In total, 53% (n=235) of participants had at least 1 visit with weight measured in the primary time window. The intervention group had a higher proportion with ≤3% weight gain at 6 months (risk ratio=1.12, 95% CI 0.94-1.28; risk difference=9.5, 95% CI -4.5 to 16.4 percentage points). This difference attenuated to the null by 24 months (risk ratio=1.00, 95% CI 0.82-1.20; risk difference=0.2, 95% CI -12.1 to 11.0 percentage points).
CONCLUSIONS: In adults with overweight or obesity receiving primary care at a community health center, we did not find long-term evidence to support the dissemination of a digital health intervention for weight gain prevention.
TRIAL REGISTRATION: ClinicalTrials.gov NCT03003403; https://clinicaltrials.gov/study/NCT03003403.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): RR2-10.1186/s12889-019-6926-7.
File size 25 with a taper of 0.06 was mounted to a 6:1 speed-reduction headpiece powered by X Smart Plus endomotor (Dentsply Maillefer, Ballaigues, Switzerland). The speed and torque were set to 400 rpm and 1 N.cm torque, respectively. In a picking motion without pressure, mechanical preparation began with the first RC two-thirds followed by the next 3 mm followed by the full WL.
### Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including nabumetone tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including nabumetone tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

### Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including nabumetone tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation.

Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit nabumetone tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if nabumetone treatment extends beyond 48 hours. Discontinue nabumetone if oligohydramnios occurs and follow up according to clinical practice [see PRECAUTIONS; Pregnancy].
<P>PROBLEM TO BE SOLVED: To provide a method for alleviating, preventing or treating symptoms of diabetes or a disorder itself, and health risks relating to diabetes.  <P>SOLUTION: A material and a method are provided which relate to mildly polar fluid extracts of plant material, such as Artemisia plant species, useful in a method for treating diabetes, a method for modulating the activity of glucagon-like peptide-1 (GLP-1), and a method for modulating phosphoenol pyruvate carboxykinase (PEPCK) activity in a diabetes-specific manner. The extracts are generally non-toxic and non-mutagenic and can be administered to diabetics with a beneficial effect on a blood glucose level. The extracts can also be administered to non-diabetics without deleterious effects. The plant is easily grown with a minimum of time, labor, and cost.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Patients presenting to the emergency department with chest discomfort who are being administered aspirin will be offered enrollment in this study. At the time of their zero and two hour troponin we will also draw platelet aggregration studies to determine the effects of aspirin upon platelets. Narcotic medicines slow the absorption of aspirin. Morphine has therefore been shown to decrease the effectiveness of aspirin. Many providers therefore use fentanyl instead, however little is known about the effects of fentanyl upon aspirin. We will therefore compare the platelet reactivity of patients receiving morphine, fentanyl, or no narcotics
This is a study of the efficacy and safety of MTG201 given by intratumoral injection to patients with malignant pleural mesothelioma who have failed front line chemotherapy. Patients will also receive IV infusions of nivolumab every 4 weeks. MTG201 is a replication incompetent adenovirus into which the gene for REIC/Dkk-3 has been inserted. The insertion of this gene has been shown to endow the adenovirus with anti-tumor activity and to result in enhanced anti-tumor immunity.

MTG201, 3 x 10E12 vp, will be given by intratumoral injection on days 1, 8, 22 and 50. Nivolumab, 480 mg, will be given by IV infusion every 4 weeks until progression. Efficacy will be assessed by CT scans at 4 and 12 weeks, then every 3 months. Safety will be assessed by reported adverse events, periodic laboratory assessments, physical exams, vital signs. The pharmacokinetics and pharmacodynamics of MTG201 will be assessed periodically. Tumor biopsy will be obtained on Days 1, 8 and 50 prior to MTG201 administration.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used for treatment of choroid tumours, complicated by secondary retinal detachment. For this purpose intravenous drop introduction of medication "Avastin" is carried out in dose 5 mg per 1 kg of patient's body weight. After that, limiting laser coagulation is performed. After two weeks transpupillar thermotherapy with infra-red laser is carried out. ^ EFFECT: method ensures efficient treatment of such pathology due to creation of favourable conditions for penetration of infra-red rays into tumour tissue as a result of preliminary elimination of screening retina action by introduction of medication "Avastatin" before carrying out laser treatment. ^ 1 ex
FIELD: medicine. SUBSTANCE: proposed agent for bilious stones dissolving at calculous cholecystitis is an organic substance - ethyl-tert.-butyl ester. Prototype of invention is methyl-tert.-butyl ester. Concrements implanted into gall of dogs (44) were dissolved. Control group (20 experiments) - the use of methyl-tert.-butyl ester. In the main group (24 experiments) ethyl-tert. -butyl ester is used. Proposed agent shows increased effectiveness and decreased pathogenicity as compared with control. EFFECT: decreased complications at calculous cholecystitis treatment, accelerated and complete dissolving bilious stones.
The invention discloses an enzyme mask, and belongs to the technical field of traditional Chinese medicine cosmetic mask production. The mask is composed of a zeolite soft peel-off enzyme mask, a pallas pit viper's gall and spirulina powder enzyme mask, a big bryozoatum paste enzyme mask, a snake oil formed enzyme mask, a medical stone and pottery clay enzyme mask, and vegetable and fruit extract and enzyme nano powder. Mask is a multi-functional cosmetic having integrated functions of cleaning, skin caring, nourishing, beautifying, wrinkle preventing, and aging resisting. The mask is painted on the facial skin, then a membrane is formed on the skin after the mask is dried for a while, and finally the mask is removed or washed away. Through the steps mentioned above, the mask can achieve the functions of nourishing the facial skin, promoting the skin metabolism, nourishing the facial skin cell, and enhancing the cell activity. Moreover, the mask also has the functions of dispelling and removing toxin, removing scurf and dirt, softening the epidermal layer, moistening and softening the skin, preventing skin wrinkles, resisting aging, beautifying, and maintaining young and beautiful.
A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions.
The invention relates to analogues of anthracyclineantibiotics covalently bound to the chitosane biopolymer, as wellto methods for their preparation. The conjugates are used asantitumour formulations with extended therapeutical range. Theyare produced from pre-oxidized chitosane the biopolymer beingoxidized by periodine acid (0.025-0.25 M), at medium pH of3.5-5.5, in a light-protected vessel, at continuous agitation for1 to 6 h. The oxidized chitosane is treated in two ways producingtwo types of conjugates. According to method A the oxidizedchitosane is treated subsequently with urea in concentration from10 to 15% and 0.9% sulphuric acid at 65°C for 10 to 16 h, 12%formaldehyde for 3 to 6 h at temepratures from 30 to 50°C and issubjected to reaction with the antracycline antibiotic in 1%concentration at pH of the medium of 7.8 for 12 h at roomtemperature and continuous agitation. By the method the oxidizedchitosane reacts with the antibiotic in a medium of dioxane/water(1:1) in the presence of a reducing agent - sodium boronhydride.Covalent bond is formed between the anthracycline antibiotics(carminomycin, daunorubicin, epirubicin and idarubicin) and thechitosane by making use of fairly low temperatures and accessible,cheap and intoxic reagents. The pH range of binding is wide andallows that the antibiotic should be immobilized at suitable pHvalues preserving its biological activity. Reaction between thematrix and the bound antibiotic is possible with the producedconjugates. The conjugates are identified by UV-VIS and IRspectra. Their antibacterial activity is preserved at the level ofthe initial compounds.3 claims
Several pieces of evidence suggest immune dysregulation could trigger the onset and modulate sequelae of new onset refractory status epilepticus (NORSE), including its subtype with prior fever known as febrile infection-related epilepsy syndrome (FIRES). Consensus-driven recommendations have been established to guide the initiation of first- and second-line immunotherapies in these patients. Here, we review the literature to date on second-line immunotherapy for NORSE/FIRES, presenting results from 28 case reports and series describing the use of anakinra, tocilizumab, or intrathecal dexamethasone in 75 patients with NORSE. Among them, 52 patients were managed with anakinra, 21 with tocilizumab, and eight with intrathecal dexamethasone. Most had elevated serum or cerebrospinal fluid cytokine levels at treatment initiation. Treatments were predominantly initiated during the acute phase of the disease (92%) and resulted, within the first 2 weeks, in seizure control for up to 73% of patients with anakinra, 70% with tocilizumab, and 50% with intrathecal dexamethasone. Cytokine levels decreased after treatment for most patients. Anakinra and intrathecal dexamethasone were mainly initiated in children with FIRES, whereas tocilizumab was more frequently prescribed for adults, with or without a prior febrile infection. There was no clear correlation between the response to treatment and the time to initiate the treatment. Most patients experienced long-term disability and drug-resistant post-NORSE epilepsy. Initiation of second-line immunotherapies during status epilepticus (SE) had no clear effect on the emergence of post-NORSE epilepsy or long-term functional outcomes. In a small number of cases, the initiation of anakinra or tocilizumab several years after SE onset resulted in a reduction of seizure frequency for 67% of patients. These data highlight the potential utility of anakinra, tocilizumab, and intrathecal dexamethasone in patients with NORSE. There continues to be interest in the utilization of early cytokine measurements to guide treatment selection and response. Prospective studies are necessary to understand the role of early immunomodulation and its associations with epilepsy and functional outcomes.
1. A method for the preparation of citalopram comprising reaction of a compound of formula IV   wherein R is Cl or Br with a cyanide source in the presence of a nickel catalyst and isolation of the corresponding 5-cyano compound citalopram as the base or a pharmaceutically acceptable salt thereof.   2. The method of Claim 1, wherein R is chloro. 3. The method of Claim 1 or 2, wherein the cyanide source is KCN, NaCN, or (R')4N CN where (R')4 indicates four groups which may be the same or different and are selected from hydrogen and straight chain or branched C1-6 alkyl. 4. The method of any of Claims 1-3, wherein the cyanide source is NaCN or KCN. 5. The method of any of Claims 1-4, wherein the nickel catalyst is Ni(PPh3)3 or (σ-aryl)-Ni(PPh)2Cl. 6. The method of any of Claims 1-5, wherein the nickel catalyst is a nickel(0) complex prepared in situ before the cyanation reaction by reduction of a nickel(II) precursor such as NiCl2 by a metal such as zinc, magnesium or manganese in the presence of an excess of complex ligands. 7. The method of Claim 6, wherein a nickel(II) precursor is NiCl2 the metal is zinc, and the complex ligands are triphenylphosphines. 8. The method of Claim 1, wherein a compound of Formula IV wherein R is Cl is reacted with NaCN or KCN in the presence of a Ni(PPh3)3 catalyst. 9. The method of Claim 8, wherein the Ni(PPh3)3 is prepared in situ before the cyanation reaction by reduction of NiCl2 by zinc, in the presence of an excess of complex triphenylphosphine ligands. 10. The method of any of Claims 1-9, wherein the reaction is carried out in the presence of a catalytic amount of Cu<+>, preferably in the form of CuI. 11. The method of any of Claims 1-9, wherein the reaction is carried out in the presence of a catalytic amount of Zn<2+>. 12. The method of any of Claims 1-11, wherein the compound of Formula IV is the S-enantiomer.
About 20.6 % of the US population smokes cigarettes. This group includes nicotine dependent smokers who are resistant to current smoking cessation treatments. Varenicline is a smoking cessation medication found in meta-analytic reviews to be superior to other smoking cessation treatments, but 56% of patients who take varenicline do not quit. One strategy to increase quit rates may be to administer a second medication to augment the efficacy of varenicline. The anti-epileptic medication zonisamide is a good candidate for adjunct treatment as it increases dopaminergic tone, normalizes glutamate homeostasis, potentiates Gamma-Aminobutyric Acid (GABA) release. Zonisamide improves sleep and promotes weight loss, two prominent issues not addressed by varenicline. Finally, the PI of this proposal has documented unpleasant changes in the taste of cigarettes and reductions in nicotine withdrawal among smokers receiving zonisamide as part of another clinical trial. The proposed study will explore the efficacy of varenicline + zonisamide for smoking cessation in a controlled, clinical trial. Eligible participants (n=60) will be smokers (\>10 cig/day for \>1 year) seeking treatment. They will be randomly assigned to receive varenicline + double-blind zonisamide or placebo for a 10-weeks. Participants will visit the clinic weekly to receive medications and smoking cessation counseling and to complete self-report questionnaires. Smoking status will be assessed via weekly urinalysis testing for cotinine (abstinence: \<200ng/ml). Cotinine is a sensitive indicator of smoking status with a longer half-life then carbon monoxide (CO) and is more likely to detect low or intermittent smoking. The study hypothesis is that participants who receive the combination zonisamide + varenicline will achieve greater smoking abstinence compared to varenicline alone. The primary outcome measure will be the 4-week rate of biochemically-confirmed continuous smoking abstinence during weeks 7-10. Secondary outcomes will include self-reported rates of smoking, subjective effects of cigarettes, weight change from baseline to week 10, sleep quality, and nicotine withdrawal severity. This study will advance the science and clinical treatment of smoking cessation, and will provide the prerequisite data to develop a larger scale clinical trial evaluation of the combination zonisamide + varenicline for smoking cessation.
BACKGROUND: Klebsiella pneumoniae (KP) accounts for high antimicrobial resistance and mortality rates of bloodstream infections (BSIs).
OBJECTIVES: To investigate incidence, antimicrobial resistance and risk factors for mortality of KP BSIs in East China.
METHODS: A retrospective study of patients with KP BSIs was conducted in a tertiary care hospital from 2018 to 2022. Medical records of all hospitalised patients with KP BSIs were reviewed and analysed. The incidence, antimicrobial resistance and mortality of KP BSIs were evaluated. The Kaplan-Meier method was used to plot survival curves and logistic regression was used to analyse risk factors for crude 30-day mortality.
RESULTS: A total of 379 inpatients with KP BSIs were enrolled. The incidence of patients with KP BSIs was fluctuating between 4.77 and 9.40 per 100,000 patient-days. The crude 30-day mortality rate of these patients was 26.39%. Of the 379 KPisolates, 197 (51.98%) were carbapenem-resistant (CR) and 252 (66.49%) were multidrug-resistant (MDR). All isolates showed the lowest resistance to tigecycline (13.77%) and polymyxin B (14.61%). Cases with MDR/CR isolates had significantly longer length of hospital stay, higher crude 30-day mortality and medical costs than non-MDR/non-CR isolates. Age, CR phenotype, paracentesis, indwelling central venous catheter (CVC), use of carbapenems, tetracyclines, polymyxins B, and irrational empiric treatment were independently associated with crude 30-day mortality.
CONCLUSION: MDR/CR KP BSIs are associated with increased mortality, healthcare costs and prolonged hospitalisation. Patients with advanced age, CR phenotype, paracentesis, CVC, exposure to some antibiotics, and irrational empirical antibiotic treatment are at higher mortality risk.
Disclosed are methods and systems for automatically estimating the length of an implantable catheter by measuring the pressure decay response to pumping fluid through the catheter. The decay time for a unit fluid pressure pulse generated within the catheter is proportional to the catheter length, i.e. as the catheter length increases so does the decay time. The catheter length can therefore be estimated based on, e.g., the decay time of the pressure pulse. The estimated catheter length can also be analyzed to determine if it is representative of the actual catheter length, or, e.g., is affected by one or more catheter malfunctions including cuts and occlusions. Systems for automatically estimating the catheter length include an implantable catheter, a pumping mechanism, a pressure sensor configured to measure pressure within the catheter, and a processor that calculates the catheter length from a pressure pulse measured while delivering fluid through the catheter.